Non-Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia – Emerging Therapies – Venclexta Launch Tracking (US) Wave 3

Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia (CLL) drug Venclexta (Roche/Genentech’s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity for Venclexta.

What you will learn in this content:

  • What is U.S. hematologist-oncologists’ awareness of and familiarity with Venclexta, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Venclexta, what are the reasons for prescribing, and how satisfied are they with Venclexta?
  • What promotional messages and activities are Roche/Genentech employing in support of the Venclexta launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Venclexta tracking compared with other recent first-in-class product launches in the oncology market?

Methodology: ~75-100 U.S. hematologist-oncologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten surveyed specialists participate in a 30-minute follow-up qualitative interview.

Related reports: Venclexta Launch Tracking (US) Wave 1, Venclexta Launch Tracking (US) Wave 2, Derzalex/Emplicity Launch Tracking (US) Wave 3

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Emerging Therapies - Venclexta Launch Tracking (US) Wave 3
    • Key Findings
      • Benchmarking Venclexta Launch Success vs. the Competition
        • Unaided Awareness of Venclexta One Year Postlaunch Is Comparable to This Awareness One Month Postlaunch
        • Benchmarking Venclexta's Launch Success vs. the Competition
      • Prescriber and Nonprescriber Profiles
        • Over Half of Prescribers and Even More Nonprescribers Do Not Know Venclexta's Cost
        • Differences Between Venclexta Prescriber and Nonprescriber Profiles
      • Venclexta Awareness and Perceptions
        • Unaided and Aided Awareness of Venclexta
          • Physician Quotes on Perceived Advantages and Disadvantages of Venclexta
          • Awareness of Venclexta
          • Physician Perception of Venclexta's Approved Indications
          • Physician Perception of Venclexta's Administration
          • Awareness of Venclexta's Price
          • Perceived Price of Venclexta
        • Familiarity with Venclexta
          • Sources of Familiarity with Venclexta
            • Venclexta Sources of Familiarity
          • Initial Reaction to and Interest in Venclexta
            • Venclexta Product Profile
            • Initial Reaction to Venclexta
            • Interest in Venclexta
          • Impressions of Venclexta
            • Physician Quotes on Impressions of Venclexta
            • Awareness of Venclexta Profile
            • Venclexta Attributes of Which Hematologist-Oncologists Were Unaware
            • Uniqueness of Venclexta
            • Value of Venclexta Characteristics
            • Mean Value of Venclexta Characteristics
            • Risk/Benefit Perception of Venclexta
          • Prescriber and Nonprescriber Profiles
          • Venclexta Trial and Use
            • Willingness to Prescribe Venclexta
              • Physician Willingness to Prescribe Venclexta to R/R CLL Patients with Del(17p)
              • Impact of Select Attributes on Physician Willingness to Prescribe Venclexta
              • Mean Value of Impact of Select Attributes on Physician Willingness to Prescribe Venclexta
              • Impact of Venclexta's Accelerated Approval Based on ORR Data of Physician Likelihood to Prescribe
            • Number of Patients Currently Receiving Venclexta
              • Venclexta Prescription Rate
              • Patient Share in the Second-Line CLL Del(17p) Setting Now and in Five Months' Time
              • Patient Share in the Third-Line CLL Del(17p) Setting Now and in Five Months' Time
              • Venclexta Discontinuation Rate Among Prescribers
              • Reasons for Discontinuing Venclexta Treatment
              • Treatment Selection Following Venclexta Discontinuation
              • Venclexta Prescribing Practices
              • Treatment Prior to Switching to Venclexta
              • Reasons for Prescribing Venclexta
              • Patient Inquiries Regarding Venclexta in Past Month
              • Physician Quotes on Patient Inquiries Regarding Venclexta
              • Mean Number of Patient Inquiries Regarding Venclexta in Past Month
              • Hematologist-Oncologists' Action Based on Specific Patient Inquiries
              • Primary Obstacles to Prescribing Venclexta to More R/R CLL Patients with Del(17p)
            • Reasons for Not Yet Prescribing Venclexta
              • Lack of Familiarity One of Two Main Reasons for Not Yet Prescribing Venclexta
              • Key Reasons for Not Yet Prescribing Venclexta
            • Anticipated Venclexta Use
              • All Current Nonprescribers Intend to Prescribe Venclexta in the Future
              • Anticipated Venclexta Use Among Nonprescribers
              • Percentage of Second-Line and Third-Line CLL Patients Eligible for Venclexta
              • Potential Displacement of Existing Treatments by Venclexta
            • Venclexta Performance on Key Attributes
              • Over Two-Thirds of Prescribers are Highly Satisfied with Venclexta
              • Overall Level of Satisfaction with Venclexta for Treatment of R/R CLL with Del(17p)
              • Level of Satisfaction with Venclexta on Key Metrics
              • Mean Levels of Satisfaction with Venclexta on Key Attributes
              • Physician Rating of Venclexta on Key Attributes
              • Performance of Venclexta on Key Attributes
          • Effectiveness of Face-to-Face Detailing for Venclexta
            • Venclexta Sales Representative Frequency and Reach
              • Forty Percent of Survey Respondents Never Visited by a Venclexta Representative
              • Last Time of Contact with a Venclexta Representative
            • Satisfaction with Venclexta Sales Representative
              • Majority of Physicians Visited by a Venclexta Sales Rep Highly Satisfied
              • Sales Representative Performance on Key Attributes
              • Sales Representative Mean Performance on Key Attributes
            • Venclexta Message Recall
              • Venclexta Dosing Frequency Discussed More Often One Year Than One Month Postlaunch
              • Topics Discussed by Sales Representatives
              • Positioning of Venclexta Against Other Products
          • Appendix
            • Key Abbreviations

        launch Related Market Assessment Reports